Avoiding Cardiovascular Events Through Combination Therapy in Patients Living With Systolic Hypertension
Terminated
Novartis
Phase 3
2003-10-01
A comparison study of two combination drugs, amlodipine/benazepril and benazepril/HCTZ to
evaluate the effectiveness of the combination on reducing heart disease and death in a high
risk hypertensive population.
Combination of Benazepril Plus Hydrochlorothiazide in Chinese Patients With Mild to Moderate Essential Hypertension
Completed
Novartis
Phase 3
2006-07-01
This study will evaluate efficacy and safety data for benazepril/hydrochlorothiazide in adult
Chinese patients with mild to moderate essential hypertension. Patients whose blood pressure
is not adequately controlled with benazepril monotherapy during a 4 week run-in period will
be randomly allocated to double blind treatment over 8 weeks with either a combination of
benazepril/hydrochlorothiazide per day or continuation of benazepril per day.
Fed Study of Benazepril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg to Lotensin HCT® Tablets 20 mg/25 mg
Completed
Mylan Pharmaceuticals
Phase 1
2002-12-01
The objective of this study was to investigate the bioequivalence of Mylan benazepril HCl and
hydrochlorothiazide 20 mg/25 mg to Novartis Lotensin HCT® 20 mg/25 mg combination tablets
following a single, oral 40 mg/50 mg (2 x 20 mg/25 mg) dose administration under fed
conditions.
Fasting Study of Benazepril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg to Lotensin HCT® Tablets 20 mg/25 mg
Completed
Mylan Pharmaceuticals
Phase 1
2002-11-01
The objective of this study was to investigate the bioequivalence of Mylan benazepril HCl and
hydrochlorothiazide 20 mg/25 mg to Novartis Lotensin HCT® 20 mg/25 mg combination tablets
following a single, oral 40 mg/50 mg (2 x 20 mg/25 mg) dose administration under fasting
conditions.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
